Improving VEGF-targeted therapies through inhibition of COX-2/PGE2 signaling.
Antiangiogenic agents targeting the vascular endothelial growth factor A (VEGFA) pathway play an important role in current cancer treatment modalities but are limited by alternative angiogenesis mechanisms. Recent studies suggest that enhanced signaling through a COX-2/PGE2 axis contributes to VEGF-independent tumor angiogenesis. Thus, COX-2/PGE2 inhibition may potentiate VEGF therapies.
Tumor Angiogenesis Section; Mouse Cancer Genetics Program; National Cancer Institute at Frederick; NIH ; Frederick, MD USA.
Lihong
L
Xu
Tumor Angiogenesis Section; Mouse Cancer Genetics Program; National Cancer Institute at Frederick; NIH ; Frederick, MD USA.
Brad St
BS
Croix
angiogenesis; axitinib; bevacizumab; celecoxib; cyclooxygenase-2 (COX-2); endothelial; metastasis; non-steroidal anti-inflammatory drugs (NSAIDs); prostaglandin E2 (PGE2); vascular endothelial growth factor (VEGF)